A phase II study of bryostatin 1 in metastatic malignant melanoma.

por Propper, D. J., Macaulay, V., O'Byrne, K. J., Braybrooke, J. P., Wilner, S. M., Ganesan, T. S., Talbot, D. C., Harris, A. L.
Publicado 1998

Phase II study of second-line therapy with DTIC, BCNU, cisplatin and tamoxifen (Dartmouth regimen) chemotherapy in patients with malignant melanoma previously treated with dacarbaz...

por Propper, D J, Braybrooke, J P, Levitt, N C, O'Byrne, K, Christodoulos, K, Han, C, Talbot, D C, Ganesan, T S, Harris, A L
Publicado 2000

Pharmacokinetically guided phase I trial of topotecan and etoposide phosphate in recurrent ovarian cancer

por Levitt, N C, Propper, D J, Madhusudan, S, Braybrooke, J P, Echeta, C, te Poele, R, Davies, S L, Flanagan, E, Hickson, I D, Joel, S, Ganesan, T S
Publicado 2005

Phase II study of RC-160 (vapreotide), an octapeptide analogue of somatostatin, in the treatment of metastatic breast cancer

por O'Byrne, K J, Dobbs, N, Propper, D J, Braybrooke, J P, Koukourakis, M I, Mitchell, K, Woodhull, J, Talbot, D C, Schally, A V, Harris, A L
Publicado 1999

Phase II study of the oxygen saturation curve left shifting agent BW12C in combination with the hypoxia activated drug mitomycin C in advanced colorectal cancer

por Propper, D J, Levitt, N C, O'Byrne, K, Braybrooke, J P, Talbot, D C, Ganesan, T S, Thompson, C H, Rajagopalan, B, Littlewood, T J, Dixon, R M, Harris, A L
Publicado 2000

Induction of thymidine phosphorylase as a pharmacodynamic end-point in patients with advanced carcinoma treated with 5-fluorouracil, folinic acid and interferon alpha

por Braybrooke, J P, Propper, D J, O’Byrne, K J, Koukourakis, M I, Patterson, A V, Houlbrook, S, Love, S D, Varcoe, S, Taylor, M, Ganesan, T S, Talbot, D C, Harris, A L
Publicado 2000